![](https://images.squarespace-cdn.com/content/v1/6616b29e6e6a4d21ed180f10/5eef49db-06ab-4f9d-b0f2-a529d71d6ed3/Banner-Clinical+Trials.jpg)
Technology
![](https://images.squarespace-cdn.com/content/v1/6616b29e6e6a4d21ed180f10/b05166a3-12a6-4fff-a6c2-cd1870c0f504/Onconano_Website+About+BandSECOND%401.25x.jpg)
Pipeline
OncoNano is building a robust pipeline to advance highly precise anti-cancer therapies.
Clinical Trials
ONM-501
OMN-501 is a nanoparticle based dual-activating STING agonist currently in clinical development for the treatment of cancer. The Phase 1 trial is examining the maximum tolerated dose, minimum effective dose and/or recommended dose for expansion of intratumoral ONM-501 as a monotherapy and in combination with a PD-1 checkpoint inhibitor, cemiplimab, in patients with advanced solid tumors and lymphomas. In the expansion phase of the study patients enroll in one to three indication-specific cohorts to assess safety and activity (NCT06022029).